Mexico Biobanks Market Report 2023 to 2030

Mexico Biobanks Market Analysis

$ 3999

The Mexico Biobanks Market was valued at $1,151.10 Mn in 2023 and is predicted to grow at a CAGR of 9.05% from 2023 to 2030, to $2,111.02 Mn by 2030. The key drivers of this industry include the prevalence of diseases, advancements in genomic research, and government and institutional support. The industry is primarily dominated by players such as Merck KGaA, Thermo Fisher Scientific, QIAGEN, and Avantor among others.

ID: IN10MXHS058 CATEGORY: Healthcare Services GEOGRAPHY: Mexico AUTHOR: Aashwi Mehta

Buy Now

Mexico Biobanks Market Executive Summary

The Mexico Biobanks Market was valued at $1,151.10 Mn in 2023 and is predicted to grow at a CAGR of 9.05% from 2023 to 2030, to $2,111.02 Mn by 2030.

A biobank is a carefully curated collection of primarily human biological samples and associated data, systematically organized for research purposes. These facilities are pivotal in medical research, aiding diverse studies such as genomics and personalized medicine. Each biobank collects samples and data tailored to its specific research goals. For example, some focus on diseases like cancer, while others gather samples and data from specific demographics or geographic regions.

The Mexican Biobank project genotyped 6,057 individuals from 898 rural and urban localities across all 32 states in Mexico, creating a valuable nationwide genotype-phenotype database. The project analyzed 1.8 Mn genetic markers, creating a comprehensive database that links genetic information with complex traits and diseases. The market is driven by significant factors like the prevalence of diseases, advancements in genomic research, and government and institutional support. However, healthcare disparities, infrastructure issues, and logistical challenges restrict the growth and potential of the market.

Prominent players in this field include Merck KGaA, Thermo Fisher Scientific, QIAGEN, and Avantor among others.

Mexico Biobanks Market Report 2023 to 2030

Market Dynamics

Market Growth Drivers

Prevalence of Diseases: In 2022, Mexico reported a tuberculosis incidence of 28 cases per 100,000 population, and 36% of adults aged 18 and above were classified as obese. These high rates of infectious and chronic diseases drive the demand for biobanks to support research and the development of effective treatments.

Advancements in Genomic Research: Advancements in genomic research and personalized medicine increase the necessity for biobanks to store and manage biological samples, supporting the creation of targeted therapies. This growing need drives the biobank market in Mexico.

Government and Institutional Support: Programs such as the Mexican Biobank project, which focuses on developing a comprehensive genotype-phenotype database, demonstrate significant governmental and institutional backing for biobanking. This support drives the biobank market in Mexico.

Market Restraints

Healthcare Disparities: Disparities between urban and rural areas in Mexico's healthcare system can affect the fair collection and distribution of biospecimens, posing a challenge to biobank market growth.

Infrastructure Issues: Mexico's healthcare infrastructure, coupled with funding challenges, can impede the development and expansion of biobanks. This limitation affects the ability to support and sustain biobanking activities across the country.

Logistical Challenges: Handling and organizing the vast amounts of biological samples and their related data is both logistically challenging and resource-intensive. This complexity can hinder the efficient operation and growth of biobanks in Mexico.

Regulatory Landscape and Reimbursement Scenario

COFEPRIS (Federal Commission for the Protection against Health Risks) is a federal agency under the Ministry of Health responsible for regulating health-related matters, including clinical trials and the ethical handling of biological materials. It is essential for approving health research and has the power to enforce penalties for violations of health regulations.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Biobanks Market:

Merck KGaA
Thermo Fisher Scientific
QIAGEN
Avantor
Becton, Dickinson and Company
Beckman Coulter
Hamilton Company
Promega Corporation
STEMCELL Technologies
Greiner Bio-One

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Biobanks Market Segmentation

By Product and Service

Equipment
Consumables
Services

By Sample Type

Blood Products
Human Tissues
Nucleic Acids
Others

By Application

Regenerative Medicine
Life Science Research
Clinical Research
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.